Key facts
- Xerient’s last known valuation is $15.3M (Feb 2025).
- It has raised $3.1M; the latest was Later Stage VC ($1.0M) in Feb 2025.
- Notable investors include Peregrine Ventures, Cancer Prevention and Research Institute of Texas, Southern Israel Bridging Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Xerient
- ·The full record, as it builds
Funding rounds
No funding rounds for Xerient are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xerient
Developer of radioprotective therapeutics designed to enhance the effectiveness and safety of pancreatic cancer. The company's therapeutics offer oral medications that protect the healthy tissues from the damaging effects of radiotherapy, enabling doctors to improve the efficacy of the treatment and reduce the need for additional procedures.
- Sector
- Healthcare
- HQ
- Petah Tikva, Israel
- Founded
- 2019
- Employees
- 2
- Website
- xerient.net/
- Ownership
- Privately Held (backing)
Xerient doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xerient shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xerient in its N-PORT filings yet. We sweep new filings monthly.